Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | HPGDS | O60760 | 1/20 | 0.30 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3694041 | 0.89 | ALDH1A1 (0.38) | PKMALDH1A1RXFP1ERN1PTGER4 | |
| SCHEMBL7492085 | 0.86 | S1PR3 (0.42) | TRPM8S1PR3S1PR1HSD17B2ALDH1A1 | |
| SCHEMBL7494518 | 0.85 | PTGER4 (0.40) | ALDH1A1PTGER4 | |
| SCHEMBL7494962 | 0.85 | PTGER4 (0.40) | ALDH1A1PTGER4 | |
| SCHEMBL7494833 | 0.81 | PKM (0.44) | PKMALDH1A1RXFP1LMNA | |
| SCHEMBL7500383 | 0.80 | HCRTR1 (0.41) | PKMRXFP1LMNA | |
| SCHEMBL7494524 | 0.80 | HCRTR1 (0.41) | PKMRXFP1LMNA | |
| SCHEMBL7494471 | 0.79 | ALDH1A1 (0.38) | PKMALDH1A1RXFP1GAAERN1 | |
| SCHEMBL1583247 | 0.78 | ERN1 (0.40) | PKMRXFP1ERN1 | |
| SCHEMBL1583278 | 0.77 | ERN1 (0.40) | PKMRXFP1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | GLAXOSMITHKLINE LLC | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | OAT, HAVCR2, CPS1 | PKM 2286/4885TRPM8 1494/4885S1PR3 3784/4885 |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | OAT, HAVCR2, CPS1 | PKM 2286/4885TRPM8 1494/4885S1PR3 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.